|
| 37039790 | Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. | JAMA | 2023 |
| 37888913 | Simvastatin in Critically Ill Patients with Covid-19. | N Engl J Med | 2023 |
| 37877585 | Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials. | JAMA | 2023 |
| 37921609 | Early oral antibiotic switch in Staphylococcus aureus bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol. | Clin Infect Dis | 2023 |
| 34518968 | Hypothermia for Patients Requiring Evacuation of Subdural Hematoma: A Multicenter Randomized Clinical Trial. | Neurocrit Care | 2022 |
| 35412625 | Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19. | JAMA Netw Open | 2022 |
| 35834252 | Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial. | JAMA Netw Open | 2022 |
| 35697146 | The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial. | Contemp Clin Trials | 2022 |
| 35717634 | The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. | Clin Infect Dis | 2022 |
| 35815677 | PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. | Leuk Lymphoma | 2022 |
| 35315874 | Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. | JAMA | 2022 |
| 33478837 | Sutureless versus conventional bioprostheses for aortic valve replacement in severe symptomatic aortic valve stenosis. | J Thorac Cardiovasc Surg | 2021 |
| 33620405 | Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial. | JAMA | 2021 |
| 34736498 | The design of a Bayesian adaptive clinical trial of tranexamic acid in severely injured children. | Trials | 2021 |
| 34606578 | Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. | JAMA | 2021 |
| 34160785 | Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials. | Ther Innov Regul Sci | 2021 |
| 34351721 | Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. | N Engl J Med | 2021 |
| 34351722 | Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. | N Engl J Med | 2021 |
| 31630567 | Comparison of methods for control allocation in multiple arm studies using response adaptive randomization. | Clin Trials | 2020 |
| 32267771 | The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. | Ann Am Thorac Soc | 2020 |
| 32198968 | Comparison of response adaptive randomization features in multiarm clinical trials with control. | Pharm Stat | 2020 |
| 32317004 | In response: Letter on update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol. | Trials | 2020 |
| 30953543 | The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. | Trials | 2019 |
| 31801567 | Update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol: statistical analysis plan for a prospective, multicenter, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. | Trials | 2019 |
| 32981939 | Optimizing Sample Size Allocation and Power in a Bayesian Two-Stage Drop-The-Losers Design. | Am Stat | 2019 |
| 30535206 | Bayesian Hierarchical Models. | JAMA | 2018 |
| 28097385 | Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. | Cancer Chemother Pharmacol | 2017 |
| 27092832 | Interpretation of Clinical Trials That Stopped Early. | JAMA | 2016 |
| 26914222 | Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. | JAMA Oncol | 2016 |
| 25268441 | Minimal clinically important difference: defining what really matters to patients. | JAMA | 2014 |
| 18283683 | Binary regression with misclassified response and covariate subject to measurement error: a bayesian approach. | Biom J | 2008 |